Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-03-01
2011-03-01
Yu, Misook (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C530S387100
Reexamination Certificate
active
07897353
ABSTRACT:
A method of detecting or monitoring a malignant plasma cell disease comprising detecting in a sample the ratio between the relative amounts of immunoglobulins having: (i) a heavy chain class bound to λ light chains; and (ii) immunoglobulins having the same heavy chain class but bound to κ light chains. Preferably the ratio is determined by (1) a method wherein the ratio is determined using: (i) an antibody, or a fragment thereof, having specificity for a heavy chain class at the same time as having specificity for a first light chain in combination with either: (ii) an antibody, or a fragment thereof, having specificity for the heavy chain class at the same time as having specificity for the second light chain; or (iii) an antibody, or fragment thereof, having specificity for the heavy chain and a further antibody, or fragment thereof, having specificity for the second light chain. (2) a method wherein the ratio is determined using: (i) at least one antibody, or a fragment thereof, specific for the heavy chain class; (ii) an antibody, or a fragment thereof, specific for λ light chains; and (iii) an antibody, or a fragment thereof, specific for κ light chains; or Antibodies specific for a heavy chain class at the same time as having specificity for a specific light chain are also provided.
REFERENCES:
patent: 3907502 (1975-09-01), Brink
patent: 4618589 (1986-10-01), Jefferis et al.
patent: 5185066 (1993-02-01), Golias
patent: 2002/0182748 (2002-12-01), Reardon
patent: 2004/0018576 (2004-01-01), DeMatteo et al.
patent: 0291194 (1994-02-01), None
patent: WO97/17372 (1997-05-01), None
patent: WO2005/116651 (2005-12-01), None
Pappas et al, 1985, Clin Immunol Immunopathology, 34: 392-396.
Shimizu et al, 1982, Clin Exp Immunol, 50: 596-600.
Briault et al, 1988, Clin Exp Immunol, 74: 182-184.
Whicher et al, 1987, Clin Chem. 33/10: 1771-1773.
Beaume et al, 1994, Blood, 84(4): 1216-1219.
Jones et al, 1991, Clin Chem, 37(11): 1922-1926.
Chersi et al, 2000, Human Immunology, 61: 1298-1306.
International Search Report and Written Opinion for PCT/GB2006/000267 filed May 24, 2006.
Abraham, R.S., et al., “Light Chain Myeloma: Correlation of Serum Nephelometric Analysis For the Quantitation of Immunoglobulin Free Light Chain With urine Bence Jones Protein” (abstract) presented at AACC Chicago, IL 2001,Clinical Chemistry, vol. 47, No. S6, pp. A33.
Anonymous: “Serum and Urine Protein Electrophoresis (SPE/UPE”, Internet Article, Oct. 12, 2004, URL:http://web.archive.org/web/20041012055838/http://www.bindingsite.co.uk/electrophoresis.asp.
Bradwell, Arthur R., et al., “Highly Sensitive, Automated Immunoassay For Immunoglobulin Free Light Chains In Serum And Urine”, 2001,Clinical Chemistry, vol. 47, No. 4, pp. 673-680.
Bradwell, Arthur R., et al., “Serum Free Light Chain Immunoassays And Their Clinical Application”, 2002,Clinical and Applied Immunology Reviews, vol. 3, pp. 17-33.
Bradwell, Arthur R., et al., “Serum Test For Assessment Of Patients With Bence Jones Myeloma”, Feb. 8, 2003,The Lancet(Reprint), vol. 361, No. 9356, pp. 489-491.
Bradwell, Arthur R., “Clinical Applications Of Serum Free Light Chain, Immunoassays”, Nov. 2003, pp 1-4, reprinted from CLI, available at http://www.bindingsite.co.uk/files/CLI.pdf.
Bradwell, Arthur R., “Serum Free Light Chain Analysis”, 2004, 2ndEdition,The Binding Site Ltd., ISBN: 07044 24541, pp. 15-16 Fig. 3.4 on p. 16, and Text on p. 15.
Bradwell, Arthur R., “Serum Free Light Chain Analysis”, 2004, 2ndEdition,The Binding Site Ltd., ISBN: 07044 24541, Chapters 4, 5, and 6, pp. 23-62.
Chui, Shiu Hon, et al., “Light-Chain Ratio Of Serum IgA1 In IgA Nephropathy”, 1991,Journal of Clinical Immunology, vol. 11, No. 4, pp. 219-223.
Haraldsson, A., et al., “Determination Of Kappa And Lambda Light Chains In Serum Immunoglobulins G, A and M”, 1991,Ann. Clin. Biochem, vol. 28, pp. 461-466.
Drayson, Mark, et al., “Serum Free Light-Chain Measurements For Identifying And Monitoring Patients With Nonsecretory Multiple Myeloma”, May 1, 2001,Blood, vol. 97, No. 9, pp. 2900-2902.
Katzmann, Jerry A., et al., “Serum Reference Intervals And Diagnostic Ranges For Free κ and Free λ Immunoglobulin Light Chains: Relative Sensitivity For Detection Of Monoclonal Light Chains”, 2002,Clinical Chemistry, vol. 48, No. 9, pp. 1437-1444.
Lachmann, Helen J., et al., “Outcome In Systemic AL Amyloidosis In Relation To Changes In Concentration Of Circulating Free Immunoglobulin Light Chains Following Chemotherapy”, 2003, British Journal Of Haematology, vol. 122, pp. 78-84.
Mead, G.P., et al., “Serum Free Light Chain Immunoassays As An Aid In The Diagnosis And Monitoring Of Light Chain Monoclonal Gammopathies”, Oct. 2001, pp. 239 (abstract) Proceedings of the Joint Annual Meeting of HSANZ and ASBT.
Mead, G.P., et al., “Nephelometric Measurement Of Serum Free Light Chains In Nonsecretory Myeloma”, 2002,Clin Chem, vol. 48, No. 6 (abstract), Presented at the AACC, FL.
Mead, G.P., et al., “Serum Free Light Chains For Monitoring Multiple Myeloma”, 2004, Blackwell Publishing Ltd,British Journal of Haematology, vol. 126, pp. 348-354.
Nakano, Takanari, et al., “ELISAs For Free Human Immunoglobulin Light Chains In Serum: Improvement Of Assay Specificity By Using Two Specific Antibodies In A Sandwich Detection Method”, 2004,Journal of Immunological Methods, vol. 293, pp. 183-189.
Sirohi, Bhawana, et al., “Multiple Myeloma”, 2004,The Lancet, vol. 363, pp. 875-887.
Prior M. et al, “Quantitation Of IgGkappa And IgGlambda In Normal And Pathological Sera,” Protides Of The Biological Fluids, vol. 29, 1981, pp. 785-788.
Jefferis R. et al, “Quantitation Of Human Total IgG, Kappa lgG And Lambda IgG In Serum Using Monoclonal Antibodies,” Journal Of Immunological Methods, vol. 39, No. 4, Dec. 28, 1980, pp. 355-362.
Derverill et al, “Monoclonal Antibodies To Human IgG: Reaction Characteristics In The Centrifugal Analyzer,” Clinical Chemistry, vol. 27/12, 1981, pp. 2044-2047.
Barnes & Thornburg LLP
Davis Minh-Tam
The Binding Site Group Limited
Yu Misook
LandOfFree
Method of detecting or monitoring a malignant plasma cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of detecting or monitoring a malignant plasma cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of detecting or monitoring a malignant plasma cell... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2757839